PALEXIA ® , an atypical opioid provides :
Strong pain relief as effective as oxycodone IR , 1 , 2 * oxycodone CR , 3 – 5 * oxycodone / naloxone MR 3 , 6 , 7 *
Different safety profile vs . oxycodone CR / IR – significantly less constipation , nausea and vomiting 1 – 5 *
* Same formulation ( IR / SR ) at equianalgesic doses . Efficacy results based on pre-specified non-inferiority criteria being met for all studies . p value not reported ; 2 , 7 p < 0.001 . 4 – 6 p < 0.001 constipation , nausea and vomiting .
PALEXIA ® IR INDICATION
For the short-term management of severe pain for which other treatment options have failed , are contraindicated , not tolerated or are otherwise inappropriate to provide sufficient management of pain . 1
PALEXIA ® SR INDICATION
For the management of severe pain where :
• other treatment options have failed , are contraindicated , not tolerated or are otherwise inappropriate to provide sufficient management of pain ; and
• the pain is opioid-responsive ; and
• requires daily , continuous , long-term treatment . PALEXIA ® SR is not indicated for use in chronic non-cancer pain other than in exceptional circumstances , or as PRN analgesia . 3
Seqirus is committed to the quality use of medicines and the responsible use of opioids where clinically indicated . For more information , please scan the QR code .
PBS Information : PALEXIA ® IR : This product is not listed on the PBS . PALEXIA ® SR : Authority Required ( STREAMLINED ). Refer to PBS schedule for full authority information .
BOXED WARNING : PALEXIA ® should be limited to patients for whom other treatment options are ineffective , not tolerated or otherwise inadequate . There are risks of hazardous and harmful use leading to overdose and death ; life-threatening respiratory depression ; and profound sedation , respiratory depression , coma and death resulting from concomitant use with benzodiazepines , alcohol and other CNS depressants . See Boxed Warning in full Product Information for further details .
Before prescribing , please review Product Information available in the Primary Advertisement in this publication or available at www . seqirus . com . au / products
REFERENCES : 1 . PALEXIA ® IR Approved Product Information . 2 . Hartrick C et al . Clin Ther 2009 ; 31 ( 2 ): 260 – 271 . 3 . PALEXIA ® SR Approved Product Information . 4 . Lange B et al . Adv Ther 2010 ; 27 ( 12 ): 981 . 5 . Lange B et al . Adv Ther 2010 ; 27 ( 6 ): 381 – 399 . 6 . Baron R et al . Pain Pract 2016 ; 16 ( 5 ): 580 – 599 . 7 . Ueberall M et al . J Pain Res 2016 ; 16 ( 9 ): 1001 – 1020 . PALEXIA ® is registered trademark of Grünenthal Pty Ltd and distributed by Seqirus ( Australia ) Pty Ltd under licence from Grünenthal Pty Ltd . Seqirus ( Australia ) Pty Ltd ABN 66 120 398 067 , Tower 1 , Level 12 Collins Square , 727 Collins Street , Melbourne VIC 3008 . www . seqirus . com . au . Medical Information : 1800 642 865 . Seqirus™ is a trademark of Seqirus UK Limited or its affiliates . Date of preparation : March 2022 . PALX-22-0029 . 001095 / A3ADG .